Caner, A. Immune escape mechanism of cancer. Curr. Mol. Biol. Rep. 10, 9–19 (2024).

Google Scholar 

Li, Y. et al. Immune cycle-based strategies for cancer immunotherapy. Adv. Funct. Mater. 31, 2107540 (2021).

CAS  Google Scholar 

Dutta, S. et al. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology 12, 218 (2023).

Messerschmidt, J. L., Prendergast, G. C. & Messerschmidt, G. L. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist 21, 233–243 (2016).

CAS  PubMed  PubMed Central  Google Scholar 

O’Connell, P. Uncovering mechanisms underlying complement-mediated cancer immune evasion. Mol. Ther. 32, 277–278 (2024).

PubMed  PubMed Central  Google Scholar 

Kim, S. K. & Cho, S. W. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front. Pharmacol. 13, 868695 (2022).

CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Castillo, M. et al. An overview of the immune modulatory properties of long non-coding RNAs and their potential use as therapeutic targets in cancer. Noncoding RNA 9, 70 (2023).

Xu, X. et al. Immunology and immunotherapy in gastric cancer. Clin. Exp. Med. 23, 3189–3204 (2023).

PubMed  Google Scholar 

Greten, T. F. et al. Immunology and immunotherapy of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 20, 349–365 (2023).

PubMed  Google Scholar 

Edwards, S. C., Hoevenaar, W. H. M. & Coffelt, S. B. Emerging immunotherapies for metastasis. Br. J. Cancer 124, 37–48 (2021).

PubMed  Google Scholar 

Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).

CAS  PubMed  PubMed Central  Google Scholar 

Riegel, K. et al. ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death Dis. 12, 969 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

O’Donnell, K. M. et al. Disruption of Gαs/cAMP-mediated acid sensing by breast tumor cells blunts tumor-induced immune suppression and decreases bone metastases by enhancing cytotoxic T cell function. Cancer Res. 85, 1212–1212 (2025).

Google Scholar 

Shimizu, K. et al. Immune suppression and reversal of the suppressive tumor microenvironment. Int. Immunol. 30, 445–455 (2018).

CAS  PubMed  Google Scholar 

Rogovskii, V. Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment. Front. Immunol. 15, 1416458 (2024).

Gurusamy, D., Clever, D., Eil, R. & Restifo, N. P. Novel “elements” of immune suppression within the tumor microenvironment. Cancer Immunol. Res. 5, 426–433 (2017).

PubMed  PubMed Central  Google Scholar 

Batlle, E. & Massagué, J. Transforming growth factor-β signaling in immunity and cancer. Immunity 50, 924–940 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Briukhovetska, D. et al. Interleukins in cancer: from biology to therapy. Nat. Rev. Cancer 21, 481–499 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Goel, H. L. & Mercurio, A. M. VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871–882 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Barbera-Guillem, E. et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62, 7042–7049 (2002).

CAS  PubMed  Google Scholar 

Pan, B. et al. TGF-β-p-STAT1-LAIR2 axis has a “self-rescue” role for exhausted CD8+ T cells in hepatocellular carcinoma. Cell Oncol. 46, 1625–1644 (2023).

CAS  Google Scholar 

Thomas, D. A. & Massagué, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).

CAS  PubMed  Google Scholar 

Viel, S. et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19–ra19 (2016).

PubMed  Google Scholar 

Choi, S. H. et al. Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells. J. Control Release 367, 768–778 (2024).

CAS  PubMed  Google Scholar 

Wang, J., Zhao, X. & Wan, Y. Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cell Mol. Immunol. 20, 1002–1022 (2023).

CAS  PubMed  PubMed Central  Google Scholar 

Tran, D. Q. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J. Mol. Cell Biol. 4, 29–37 (2012).

CAS  PubMed  Google Scholar 

Sullivan, K. M. et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut 72, 325 (2023).

CAS  PubMed  Google Scholar 

Oft, M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2, 194–199 (2014).

CAS  PubMed  Google Scholar 

Littwitz-Salomon, E., Malyshkina, A., Schimmer, S. & Dittmer, U. The cytotoxic activity of natural killer cells is suppressed by IL-10+ regulatory T cells during acute retroviral infection. Front. Immunol. 9, 1947 (2018).

Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746–756 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Rivas, J. R. et al. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia 35, 3188–3200 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Mimura, K. et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother. 56, 761–770 (2007).

CAS  PubMed  Google Scholar 

Oussa, N. A. E. et al. VEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation. J. Immunol. 197, 3927–3935 (2016).

CAS  PubMed  Google Scholar 

Aguiar, R. B. d. & Moraes, J. Z. d. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors. Front. Immunol. 10, 1023 (2019).

Iglesias-Escudero, M., Arias-González, N. & Martínez-Cáceres, E. Regulatory cells and the effect of cancer immunotherapy. Mol. Cancer 22, 26 (2023).

CAS  PubMed  PubMed Central  Google Scholar 

Li, Y. et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J. Transl. Med. 22, 293 (2024).

PubMed  PubMed Central  Google Scholar 

Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16–25 (2019).

CAS  PubMed  Google Scholar 

Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).

CAS  PubMed  PubMed Central  Google Scholar 

Li, X. et al. Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy. Front. Immunol. 12, 754196 (2021).

Zheng, Y. et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis. 15, 775 (2024).

PubMed  PubMed Central  Google Scholar 

Sangsuwan, R. et al. Lactate exposure promotes immunosuppressive phenotypes in innate immune cells. Cell Mol. Bioeng. 13, 541–557 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Hayes, C., Donohoe, C. L., Davern, M. & Donlon, N. E. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. Cancer Lett. 500, 75–86 (2021).

CAS  PubMed  Google Scholar 

Fischer, K. et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood 109, 3812–3819 (2007).

CAS  PubMed  Google Scholar 

Wu, H. et al. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat. Commun. 11, 4113 (2020).

CAS  PubMed  PubMed Central